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Abstract
Patents for the first generation of approved biopharma-
ceuticals have either expired or are about to expire. Thus
the market is opening for generic versions, referred to as
‘biosimilars’ (European Union) or ‘follow-on protein prod-
ucts’ (United States). Healthcare professionals need to un-
derstand the critical issues surrounding the use of biosimi-
lars to make informed treatment decisions.
The complex high-molecular-weight three-dimensional
structures of biopharmaceuticals, their heterogeneity and
dependence on production in living cells makes them dif-
ferent from classical chemical drugs. Current analytical
methods cannot characterize these complex molecules suf-
ficiently to confirm structural equivalence with reference
molecules. Verification of the similarity of biosimilars to
innovatorbiopharmaceuticalsremainsakeychallenge.Fur-
thermore,acriticalsafetyissue,theimmunogenicityofbio-
pharmaceuticals, has been highlighted in recent years, con-
firming a need for comprehensive immunogenicity testing
priortoapprovalandextendedpost-marketingsurveillance.
Biosimilars present a new set of challenges for regula-
toryauthoritieswhencomparedwithconventionalgenerics.
While the demonstration of a pharmacokinetic similarity is
sufficient for conventional, small-molecule generic agents,
a number of issues will make the approval of biosimilars
more complicated. Documents recently published by the
European Medicines Agency (EMEA) outlining require-
mentsforthemarket approval ofbiosimilarsprovide much-
needed guidance. The EMEA has approved a number of
biosimilarproductsinascientificallyrigorousandbalanced
process. Outstanding issues include the interchangeability
of biosimilars and innovator products, the possible need
for unique naming to differentiate the various biopharma-
ceutical products, and more comprehensive labelling for
biosimilars to include relevant clinical data.
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Introduction
The first-generation biopharmaceuticals are copies of en-
dogenoushumanproteins,suchaserythropoietin(EPO),in-
sulin, growth hormones and cytokines that were developed
using recombinant DNA (rDNA) technology or hybridoma
techniques.Thesecompoundshaverevolutionizedthetreat-
ment of many diseases, including anaemia, diabetes, can-
cer, hepatitis and multiple sclerosis [1]. Patents for many
first-generation biopharmaceuticals have either expired or
are about to expire. This has opened the market to non-
innovator versions of these products, called ‘biosimilars’ in
the European Union, and ‘follow-on protein products’ in
the United States. The European Union has established le-
gal and regulatory pathways for bringing biosimilars to the
market [2–10], while the United States has yet to establish
similar pathways [11].
Biosimilars are defined as biological products similar,
but not identical, to reference products that are submitted
for separate marketing approval following patent expira-
tion of the reference products [3,12–14]. Biosimilars are
not generic versions of innovator products. Conventional
generics are considered to be therapeutically equivalent to
a reference once pharmaceutical equivalence (i.e. identi-
cal active substances) and bioequivalence (i.e. comparable
pharmacokinetics)havebeenestablishedanddonotrequire
formal clinical efficacy and safety studies. The term ‘bio-
generic’ wouldimplythattheactive substance ofabiosimi-
lar could be readily characterized and shown to be identical
to the active substance of the reference product. This is
simply not the case with biosimilars. The active substance
of a biopharmaceutical is a collection of large protein iso-
forms and not a single molecular entity, which is generally
the case with conventional small-molecule drugs. Thus, it
is highly unlikely that the active substances are identical
between two products, and there are currently no analyti-
cal techniques to establish biopharmaceutical equivalence
[12]. Table 1 shows standard definitions for conventional
generic agents, biopharmaceuticals and biosimilars based
on terminology used by the European Medicines Agency
(EMEA) [3,4,12].
Biosimilars present a new set of challenges compared
with conventional generics, and their market approval is
more complicated. The complexity of biopharmaceuticals
makes it difficult to avoid heterogeneity between batches
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Table 1. Definitions of biological and chemical pharmaceuticals
Generic drug Chemical and therapeutic equivalent of a
low-molecular-weight drug whose patent has
expired
Biopharmaceutical ‘A medicinal product developed by means of one
or more of the following biotechnology
practices: rDNA, controlled gene expression,
antibody methods’a
Biosimilar ‘A biological medicinal product referring to an
existing one and submitted to regulatory
authorities for marketing authorization by an
independent application after the time of the
protection of the data has expired for the
original product’a
Data from Crommelin et al. [12], reprinted with permission from Pharma
Publishing & Media Europe. Copyright 2006. All rights reserved.
aEuropean Agency for the Evaluation of Medicinal Products definition.
from the same manufacturing process and between the
same proteins from different manufacturers [12]. More-
over, it is difficult to establish therapeutic equivalence of
biosimilars with reference products without clinical trials
[13,15,16]. Safety of biosimilars is also a critical consid-
eration. An important difference between biopharmaceu-
ticals and conventional drugs with regard to safety is the
significant potential to induce an immune response (im-
munogenicity) [10,17,18]. Documents recently published
by the EMEA outlining requirements for market approval
of biosimilars provide much-needed guidance [19]. The
EMEAalsoprovidespublicassessmentreportsforbiophar-
maceutical products that include the summary of product
characteristics and a scientific discussion of the clinical
data supporting approval. As of January 2008, the EMEA
has advised approval of biosimilar versions of recombinant
somatropin [20,21], recombinant human EPO (rHuEPO)
[22–26] and filgrastim [27]. One follow-on somatropin
product has been approved in the United States, but ad-
ditional approvals of follow-on protein products will ne-
cessitate the establishment of a formal legal and regulatory
pathway in the United States [11].
Clinicians need to be aware of the important issues sur-
rounding the use of biosimilars. Greater awareness of the
potential differences between products will enable clini-
cians to make informed prescribing decisions, which are
critical for patient safety. This article will highlight some
of the main issues with biosimilars and review the current
status of regulatory approval procedures and biosimilars
that have been approved by the European Union.
Key issues with biosimilars
Manufacture
The complexity of the manufacturing process for biophar-
maceuticals is several orders of magnitude higher than
thatforsmall-moleculepharmaceuticals[12].Conventional
pharmaceutical agents are small-molecule chemicals with
a defined molecular weight typically between 100 and
1000Da.Incontrast,biopharmaceuticalsarelarge,complex
and heterogeneous proteins with more variable molecular
weights, commonly ranging from 18 000 to 145 000 Da.
Compared to the manufacture of small molecular entities,
the manufacture of biopharmaceuticals requires a greater
number of batch records (>250 versus <10); more product
quality tests (>2000 versus <100); more critical process
steps (>5000 versus <100) and more process data entries
(>60000versus<4000)[28].Themolecularsizeandcom-
plexityofbiopharmaceuticalsandtheirproductioninliving
cells makes the final product very sensitive to changes in
production conditions. Changes may occur to the expres-
sion systems used for production, culture conditions (e.g.
temperatureandnutrients),purificationandprocessing,for-
mulation, storage and packaging.
Small changes in, or differences between, manufactur-
ing processes may have a significant impact on the qual-
ity, purity, biological characteristics and clinical activity of
the final product [12,13,15,18,29]. Even when biosimilars
are produced from the same genetic construct, using the
same technique, formulation and packaging as the innova-
tor product, there is no guarantee that they will be com-
parable with the reference product. Structural differences
betweenproteinsmayariseforanumberofreasons,includ-
ingoligomerization,modificationoftheproteinprimaryse-
quence, glycosylation patterns or the conformational state.
In order to maximize comparability between batches,
manufacturers of both innovator and biosimilar products
must ensure consistency in their production processes and
perform rigorous purity and activity profiling. Various an-
alytical tests are available to evaluate the physicochemical
properties. However, it is important to recognize the limita-
tions of existing assays [15,16]. For example, subtle differ-
ences in the conformational state of a recombinant protein
product can be very difficult to detect even with state-of-
the-art analytical techniques. Quality assurance assays for
biopharmaceuticals are generally less sensitive and precise
than tests for small-molecule drugs. There is also a need
to standardize assays to enable the comparison of results
obtained from different laboratories. Until such standard-
ization is achieved, only data obtained within the same lab-
oratory can be compared. For these reasons, it is difficult to
establish biopharmaceutical equivalence (i.e. equivalence
for the active substance) between a biosimilar and a refer-
ence product. Furthermore, even if molecular characteris-
ticsandbioavailabilityaresimilarbetween products,itcan-
not be assumed that their clinical activity will be the same.
The only way to ascertain the safety and efficacy of a
biosimilar will be to conduct pre-clinical tests and clinical
trialsandimplementtailoredpharmacovigilanceplans[16].
Guidelines published by the EMEA detailing requirements
for approval of biosimilars [19] are described later in this
article.
Variability
While no biosimilars have been approved yet in the United
States and biosimilar products were only recently intro-
duced in the European Union, a number of alternative
copies of innovator biopharmaceuticals have been avail-
able in South America and the Asia-Pacific region. An-
alytical studies have revealed the extent of heterogeneity
of biopharmaceuticals produced by different manufactur-
ing processes around the world. Variation is illustrated by aBiosimilar therapeutics i29
number of studies of innovator and non-innovator versions
of rHuEPO. Key differences have been found in the struc-
ture, stability, composition, concentration and activity of
manufactured epoetins [30–32].
EPO is a 165-amino-acid glycoprotein that stimulates
erythropoiesis. Erythropoiesis-stimulating agents (ESAs),
based on rHuEPO, have been used successfully for more
than 17 years for the treatment of anaemia associated with
chronic kidney disease (CKD) or cancer therapy [33,34].
There are a number of first-generation ESAs available in
the United States and Europe. Epogen
R  (epoetin alfa) and
Procrit
R  (epoetin alfa), manufactured by Amgen, USA,
are currently available in the United States. Eprex
R  (epo-
etin alfa), manufactured by Ortho Biologics LLC, USA,
and marketed by Johnson & Johnson, is available outside
the United States. NeoRecormon
R  (epoetin beta), man-
ufactured by Roche, Basel, Switzerland, is available in
Europe. In addition, Aranesp
R  (darbepoetin alfa), manu-
factured by Amgen, USA, is available in the United States,
Europe, Canada and Australia, and MIRCERA
R  (methoxy
polyethylene glycol-epoetin beta), manufactured by Roche,
Basel, Switzerland, is available in Europe.
Three non-innovator products for epoetin alfa are now
manufacturedinKorea(Eporon
R ,Dong-APharmaceutical
CompanyLtd;Espogen
R ,LGLifeSciences;Epokine
R ,CJ
Corporation). However, all three brands have been shown
to differ from the reference epoetin alfa product manufac-
tured by Amgen (Epogen
R ), with variations in the activity,
concentration and isoforms of the products [30]. For ex-
ample, iso-electric focusing demonstrated the presence of
additional isoforms in all three products from Korea com-
paredwithEpogen
R ,despiteclaimsoftheirsubstitutability
and bioequivalence. An in vitro bioassay showed that both
Eporon
R  and Espogen
R  had a higher bioactivity than was
listed on their respective labels. In addition, an enzyme-
linked immunosorbent assay indicated that both of these
products had higher concentrations of epoetin alfa than
stated on the product labels.
In another study, differences in structure and stability
were also found between intravenous formulations of epo-
etin alfa produced by two different manufacturers. A bio-
physical comparison of Epogen
R  (Amgen) with Eprex
R 
(manufactured by Ortho Biologicals LLC and distributed
by Johnson & Johnson) showed that the two products were
not structurally identical. Small differences were found in
the hydrodynamic structure, the degree of alfa helicity and
the stability of these products [31].
Combe et al. [32] evaluated literature reports of studies
conducted with non-innovator epoetin products marketed
outside the United States and the European Union. The
authors found that analytical studies failed to demonstrate
comparability of non-innovator epoetins to the reference
product. Products differed in composition, did not consis-
tently meet declared specifications and displayed variation
between batches. Additional compounds were detected in
3 of 11 biosimilar products analysed, compared with the
reference product, and additional epoetin isoforms were
detected in 9 of 11 cases. Furthermore, an in vivo bioas-
say in mice demonstrated that bioactivity was higher than
specificationsinfoursamples(137–226%)andbelowspec-
ifications in two samples (71–75%; Figure 1) [32,35]. In
addition, few of the clinical evaluations were competitor
controlled and studies were not thorough enough to show
equivalent safety and efficacy of the biosimilar products to
the innovator epoetin alfa.
The variation between products manufactured by dif-
ferent companies underscores the challenge in producing
biopharmaceutical proteins to consistent standards. While
thesenon-innovatorproductsarenotbiosimilars,theyillus-
trate the difficulties facing regulators to ensure the quality
and safety of biosimilar products. Biosimilar epoetins and
other biosimilar products have been recently approved in
Europe and are discussed in detail below.
Impact on patient safety
Differences between biological protein products claiming
to be similar to approved biopharmaceuticals have been
a major concern for the industry and regulatory agencies
worldwide. The intrinsic structural and physicochemical
heterogeneity of biopharmaceuticals and the complex man-
ufacturing process has the potential to affect their safety
and efficacy [13,15,18].
The primary safety concern for biosimilar agents is their
potentialimmunogenicity[17].Theuseofbiopharmaceuti-
cals to replace endogenous proteins, which may be present
at insufficient concentrations (e.g. the use of ESAs in CKD
patients with anaemia), carries the serious risk of stimulat-
ing the immune system to develop anti-product antibodies
(Abs) that may cross-react with endogenous protein [17].
Although these proteins are designed to closely mimic hu-
man proteins, they have the potential to induce an immune
response, especially when administered as multiple doses
over prolonged periods [36,37]. The level of immunogenic-
ity can be markedly different for products considered to
be very similar. Computer algorithms can help in the de-
sign of less immunogenic proteins [38]. However, no single
technique can definitively predict the immunogenicity of a
particular protein.
There may be no clinical consequence for developing
an immune response to a biopharmaceutical. The patient
may develop binding Abs that do not significantly affect
the activity of the biopharmaceutical or endogenous pro-
tein. On the other hand, anti-product Abs can bind to, and
attenuate the activity of, a biopharmaceutical, and general
effects include allergy, anaphylaxis or ‘serum sickness’.
Major clinical impact can occur if the endogenous protein
with essential biological activity is also neutralized. For ex-
ample, neutralizing naturally occurring EPO can result in a
rare condition known as Ab-mediated pure red cell aplasia
(PRCA).
One commonly cited example of the impact of variabil-
ity between biological products on safety is the large in-
creaseintheincidenceofAb-mediatedPRCAoccurringbe-
tween1998and2003inCKDpatientswithanaemiatreated
with Eprex
R , a formulation of epoetin alfa, marketed by
Johnson&Johnson(Figure2)[18,39–42].ThePRCAcases
were associated with a breakdown of immune tolerance to
treatmentwithrHuEPO,particularlywithsubcutaneousad-
ministration, resulting in neutralizing Ab formation against
both recombinant and endogenous EPO [43]. Previously,
PRCA caused by the production of neutralizing anti-EPOi30 H. Schellekens
Fig. 1. Physicochemical and biological characteristics of non-innovator epoetin products available outside of the United States and Europe.
(A) Isoelectric focusing (i)/ western blot (ii) isoform distribution of 11 non-innovator epoetins compared to Eprex
R  (E). The table shows the location
where each sample was obtained. (B) Bioactivity, determined by an in vivo bioassay in mice, was higher than specifications in four samples (137–226%)
and below specifications in two samples (71–75%) [35].
Fig. 2. Antibody-mediated pure red cell aplasia (PCRA) cases, 1997–
2002. Data from Schellekens [18], by permission of Oxford University
Press.
AbsoccurredveryrarelywithESAtreatment.Theapparent
increase in immunogenicity coincided with a relatively mi-
nor formulation change for Eprex
R —replacement of hu-
manserumalbuminasastabilizerwithglycineandpolysor-
bate 80 in 1998. A contraindication for subcutaneous ad-
ministration led to a subsequent decrease in the incidence
of PRCA.
The Eprex
R  case highlights concerns regarding the un-
predictability and seriousness of immunogenicity of bio-
pharmaceuticals and the potential clinical consequences
of their extensive use. Only a small change in the man-
ufacturing process appears to have altered the product’s
characteristics with a drastic impact on clinical outcome.
Many factors have the potential to influence the immuno-
genicity of proteins. These include variation in amino acid
sequence or glycosylation patterns, denaturation or aggre-
gation caused by oxidation due to storage conditions, the
presence of contaminants or impurities in the preparation,
dose, route of administration, treatment duration and the
genetic characteristics of patients [18].
The mechanism by which Eprex
R  induced PRCA is still
not fully understood. A number of possible causes have
been proposed [43–45]. These are primarily either micelle
formation from polysorbate 80 and epoetin alfa [44,46] or
leachates from rubber stoppers breaking B-cell tolerance
via an adjuvant effect [45,47,48]. Although many factors
are reported to influence the immunogenicity of therapeu-
tic proteins, aggregates play a role in the majority of cases.
The Eprex
R  preparation showed an increase in the levels
of aggregates during storage, although the level was never
reported to have exceeded specifications. However, prod-
uct specifications are not defined on the basis of biologi-
cal effects and aggregates may still be relevant for PRCA
induction.
Although cases of Ab-mediated PRCA are rare (ranging
from 0.2 to 18 cases per 100 000 patient-years between
2001 and 2003 for the various ESA products [39]), it is a
serious complication and one that requires patients to be
treated with multiple blood transfusions. The increase in
Ab-mediated PRCA cases associated with Eprex
R  in 1998
highlights how a difference in the manufacturing process
can alter product characteristics. This example illustrates
just one of the issues to be considered when dealing with
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of biosimilar epoetins, understanding the cause of Ab-
mediated PRCA associated with Eprex
R  is important for
future patient safety [49].
In relation to this issue, it is also important to be aware
of the different immunogenic profiles that regulatory ap-
proved biosimilars have versus their ‘similar biological
medicinal products’ (SBMPs). For example, a biosimilar
epoetin zeta product [SB309 (Retacrit
R )] manufactured by
Hospira showed a marked difference in immunogenicity in
dogs compared with epoetin alfa (its SBMP), although the
Abswerenon-neutralizingandwerenotassociatedwithany
deterioration in the case of the animals [50]. While there is
no hint that SB309 will be more immunogenic than epoetin
alfa (at least with respect to clinically relevant neutraliz-
ing Abs), only longer term clinical data can fully address
the relevance of this difference in immunogenic profile in
animals.
A recent case report has documented an instance of
PRCA in a haemodialysis patient with CKD ∼6 months
after treatment with the follow-on epoetin alfa Wepox
R 
(Wockhardt Ltd, Mumbai, India) [51]. The precise mech-
anism for the development of PRCA in this patient has
not been elucidated. However, authors suggest that, as
for Eprex
R , the increase in immunogenicity could have
been due to problems in the manufacturing and storage of
Wepox
R .
Regulatory approval
General
Limited documentation is required to obtain marketing au-
thorizationforaconventionalsmall-moleculegenericdrug.
In general, it is sufficient to show pharmaceutical equiva-
lence and bioequivalence of a generic drug compared with
the original product in a small study of volunteers, via an
abridged procedure. However, this approach cannot be ex-
trapolated to the majority of biopharmaceuticals because
current analytical methods are inadequate to fully charac-
terize these complex proteins. The amount of data required
for market approval of biosimilars will be more than for a
typical generic drug application but less than for a full new
biopharmaceutical application.
EMEA guidelines
TheEMEA’sCommitteeforMedicinalProductsforHuman
Use (CHMP) have issued a number of guidelines relevant
to biosimilars that detail the requirements for market ap-
proval (Table 2). Biosimilar products will be approvable
if they have a reference branded market-approved product
for which the data protection period has expired. In the
United States, the Food and Drug Administration does not
have the legal authority to approve most follow-on biolog-
ics, and therefore, has not yet issued a specific regulatory
pathway. The EMEA guidelines advocate pre-clinical and
clinical testing of biosimilars to demonstrate safety and ef-
ficacy prior to market authorization, followed by tailored
pharmacovigilance plans to monitor potential immuno-
genicity [10,14,16,19].
The EMEA guidelines cover a range of issues includ-
ing manufacturing, measurement of comparability, physic-
ochemicalandbiologicalanalysesandclinicaltrialrequire-
ments. In addition to the pharmaceutical, chemical and
biological data normally required for a generic drug ap-
plication, applications for the market approval of biosimi-
lar products will require additional toxicological and other
non-clinical and clinical data. The goal will be to demon-
strate that the biosimilar product is similar to the reference
product in terms of quality, safety and efficacy. Products
will be dealt with on a case-by-case basis, which reflects
the complexity and diversity of the products under review.
Updates to the guidelines will be published on the EMEA
website (www.emea.europa.eu).
The EMEA/CHMP issued an overarching biosimilars
guideline[3]tosetthesceneandguidelinesforthedevelop-
mentofbiosimilarscoveringqualityissues[4],non-clinical
andclinicalissues[9]andimmunogenicityforbothbiosim-
ilars and innovator products that undergo a manufacturing
change [10]. In addition, the EMEA/CHMP released four
product class-specific guidelines or concept papers [5–8].
Brief details of these guidelines are outlined below:
• The Guideline on similar biological medicinal products,
which came into effect in October 2005 had the purpose
of ‘introducing the concept of similar biological prod-
ucts, outlining the basic principles to be applied and pro-
viding applicants with a “user guide” showing where to
find relevant scientific information in the various CHMP
guidelines,inordertosubstantiatetheclaimofsimilarity’
[3].
• The Guideline on similar biological medicinal products
containing biotechnology-derived proteins as active sub-
stance: quality issues came into effect in June 2006. The
aim of this document is to ‘lay down the quality require-
ments for a biological medicinal product claiming to be
similartoanotheronealreadymarketed’[4].Importantly,
this guideline addresses the requirements regarding man-
ufacturing processes, analytical methods to assess com-
parability, factors to consider when choosing a reference
product and physicochemical and biological characteri-
zation of the SBMP.
• The Guideline on similar biological medicinal products
containing biotechnology-derived proteins as active sub-
stance: non-clinical and clinical issues also came into
effect in June 2006. This guideline ‘lays down the non-
clinical and clinical requirements for a biological medic-
inal product claiming to be similar to another one already
marketed’ [9]. The non-clinical section addresses the
pharmaco-toxicological assessment. The clinical section
addressestherequirementsforpharmacokinetic,pharma-
codynamic,efficacyandsafetystudies,withemphasison
the evaluation of immunogenicity of the SBMP.
• The Guideline on immunogenicity assessment of
biotechnology-derived therapeutic proteins came into
effect in April 2008 [10]. This guideline provides
a broad overview of the immunogenic issues that
biopharmaceutical companies must adequately address
for the approval of a biosimilar product or when a manu-
facturing change occurs. The guideline discusses factorsi32 H. Schellekens
Table 2. European Medicines Agency (EMEA) guidelines for biosimilars
Guideline Focus Released for consultation Came into effect
EMEA/CHMP/437/04: Guideline on similar biological medicinal
products [3]
General Nov. 2004 Oct. 2005
EMEA/CHMP//BWP/49348/05: Guideline on similar biological
medicinal products containing biotechnology-derived proteins as
active substance: quality issues [4]
Quality issues March 2005 June 2006
EMEA/CHMP/BMWP/42832/05: Guideline on similar biological
medicinal products containing biotechnology-derived proteins as
active substance: non-clinical and clinical issues [9]
Non-clinical and clinical issues May 2005 June 2006
EMEA/CHMP/BMWP/14327/06: Guideline on immunogenicity
assessment of biotechnology-derived therapeutic proteins [10]
Immunogenicity assessment Jan. 2007 April 2008
EMEA/CHMP/94528/05: Annex to guideline on similar biological
medicinal products containing biotechnology-derived proteins as
active substance: non-clinical and clinical issues; guidance on
similar medicinal products containing somatropin [6]
Recombinant somatotropin May 2005 June 2006
EMEA/CHMP/32775/05: Annex to guideline on similar biological
medicinal products containing biotechnology-derived proteins as
active substance: non-clinical and clinical issues; guidance on similar
medicinal products containing recombinant human insulin [7]
Recombinant human insulin May 2005 June 2006
EMEA/CHMP/31329/05: Annex to guideline on similar biological
medicinal products containing biotechnology-derived proteins as
active substance: non-clinical and clinical issues; guidance on
similar medicinal products containing recombinant G-CSF [8]
Recombinant G-CSF June 2005 June 2006
EMEA/CHMP/94526/05: Annex to guideline on similar biological
medicinal products containing biotechnology-derived proteins as
active substance: non-clinical and clinical issues; guidance on
similar medicinal products containing recombinant EPOs [5]
Recombinant EPO May 2005 July 2006
EPO, erythropoietin; G-CSF, granulocyte-colony-stimulating factor.
that might influence immunogenicity and the potential
consequences of immunogenicity; the development, de-
sign and interpretation of non-clinical and clinical assays
to evaluate the immunogenic potency of a product and its
comparability to other products; and the implementation
of a risk management plan. Many of the concepts dis-
cussed in the guideline will likely need to be adapted on
a case-by-case basis.
• Four product class-specific guidelines were issued for
the development of biosimilars containing recombinant
EPO [5], somatotropin [6], human insulin [7] and human
granulocyte colony-stimulating factor [8]. These docu-
ments outline pre-clinical and clinical data requirements
for marketing approval, describing the size of the trials
required and the best indication for demonstrating equiv-
alence for each product, in comparison with a reference
product.
One example of the product-specific guidelines is the
EMEA Annex to the guideline on similar biological medic-
inal products containing biotechnology-derived proteins as
activesubstance:non-clinicalandclinicalissues;guidance
on similar medicinal products containing recombinant ery-
thropoietins. This guideline was effective from July 2006
and ‘lays down the non-clinical and clinical requirements
for EPO-containing medicinal products claiming to be sim-
ilar to another one already marketed’ [5]. Interestingly, the
regulatory requirements are more stringent for EPO than
for the other recombinant proteins, reflecting its greater
molecularcomplexityandclinicalhistory(i.e.Ab-mediated
PRCA). Equivalent therapeutic efficiency with the refer-
ence product must be demonstrated in at least two ran-
domized,parallel-groupclinicaltrials,whicharepreferably
double-blind. The document also states that patients with
renal anaemia would be the best study population and that
afteraninitialtitrationphase,thecomparativephaseshould
be at least 12 weeks, followed by a maintenance study of
at least 3 months. Therapeutic equivalence must be demon-
strated for both predialysis and haemodialysis CKD pa-
tients, and by both the intravenous and subcutaneous routes
of administration. Clinical trials should involve at least 300
patients, and at least 12 months of immunogenicity data
should be provided.
Recently, both France and Spain adopted legislation pre-
venting the automatic substitution of a biological medicine
for a biosimilar. This decision transposes into French law
the European Directive 2004/27/EC [2] governing the def-
inition of generic and biosimilar medicines. Thus, French
and Spanish law now forbids the replacement of one bio-
logical medicine for another at the pharmacy without the
express consent of the prescribing physician.
Post-marketing surveillance
The onset and incidence of immunogenicity is unpre-
dictable; therefore, extended post-marketing surveillance
(pharmacovigilance) to monitor potential immunogenic-
ity is very important [14,16]. Biosimilar guidelines from
the EMEA state that a pharmacovigilance plan to address
immunogenicity and potential rare adverse events should
be included in the data package submitted for the product
approval[5–9].Theterm‘pharmacovigilance’describesthe
detection, assessment, understanding and prevention of ad-
verse effects after the launch of a product onto the market.Biosimilar therapeutics i33
Asalreadydiscussedpreviously,thereareimportantlessons
to be learned from the experience with Eprex
R  and Ab-
mediated PRCA. Although the innovator product had been
in use for years, it was some time before the link between
the relatively small modification in the product formula-
tion and the increase in the number of PRCA cases was
established [17].
Current biosimilars
Because of the benefits and potential risks associated with
biopharmaceuticals and biosimilars, it is important that
cliniciansfamiliarizethemselveswiththerelevantliterature
on the safety and efficacy of these agents in various patient
populations. The EMEA provides information on the ap-
proval process for human medicines [the European Public
Assessment Report EPAR)], including a scientific discus-
sion on the clinical data submitted for approval. Generally,
theEPARsforbiosimilarshavestatedthatthebiosimilarre-
ceived approval because it was shown to have a comparable
quality, safety and efficacy profile to the reference product
[52–58]. Despite the comparability of these biosimilars to
the reference products, clinicians should be aware of some
of the issues that emerged during the development and ap-
proval of these products, which highlight the challenges of
biosimilars.
Two biosimilar somatropins, Omnitrope
R  and Valtr-
opin
R  (marketed by Sandoz and Biopartners, respectively)
havebeenapprovedbytheEMEA.Omnitrope
R  isabiosim-
ilar version of the reference product, Genotropin
R  (man-
ufactured by Pfizer). Like Genotropin
R , Omnitrope
R  is a
recombinant form of human somatropin that is manufac-
tured with rDNA technology in E. coli. The comparability
of Omnitrope
R  to Genotropin
R  was demonstrated in a ran-
domizedcontrolledtrialin89childrenwithalackofgrowth
hormone, with an additional safety study performed in 51
children [52]. During the development of Omnitrope
R ,a n
immunogenicity issue emerged with an early version of
the product. Up to 60% of patients enrolled in two clinical
studies developed anti-growth hormone Abs, which did not
appear to affect growth rate. The cause of immunogenic-
ity was linked to excess host cell protein contamination,
which was resolved by the manufacturer with additional
purification steps [59]. Valtropin
R , a biosimilar version
of Humatrope
R  manufactured by BioPartner, was shown
to have similar efficacy and safety to the reference prod-
uct in a 12-month randomized controlled trial involving
149 children lacking growth hormone [53,60]. Clinicians
should be aware that while these products have comparable
active substances, Humatrope
R  is synthesized in E. coli
and Valtropin
R  is synthesized in the yeast Saccharomyces
cerevisiae.
Five biosimilar rHuEPOs that are manufactured by two
companieshavebeenapprovedbytheEMEA.Abseamed
R ,
Binocrit
R  andEpoetinalfaHEXAL
R  areepoetinalfaprod-
ucts and are biosimilar versions of the reference product
Eprex
R , all produced by Rentschler Biotechnologie GmbH
but marketed by three different companies. The approval
of these biosimilar epoetin alfa products was based on the
demonstration of comparability with Eprex
R  in quality,
safety and efficacy. Comparability exercises demonstrated
that although the active substance of the biosimilars was
representativeoftheactivesubstanceisolatedfromEprex
R 
by immunoaffinity chromatography [61–63], there was a
difference in glycosylation levels. The biosimilars con-
tained higher levels of high-mannose-type structures, but
this difference was not thought to be clinically significant.
Comparable safety and efficacy between these three
biosimilar epoetin alfa products and Eprex
R  was demon-
strated in a randomized controlled trial involving 479
haemodialysis patients with renal anaemia [56–58]. Al-
though the regulatory guidelines for biosimilar rHuEPO
developed by the EMEA recommend that comparable ef-
ficacy and safety are demonstrated with two randomized
trials in the nephrology setting [5], the biosimilar epoetin
alfa products were approved based on a single nephrology
trial.Datafromastudyinvolving114cancerpatientsreceiv-
ing chemotherapy were also submitted for approval but this
studywasnotadequatelypoweredtodemonstratetherapeu-
ticequivalencetothereferenceproduct[61–63].Biosimilar
epoetin alfa was approved for indications in cancer patients
and patients planning to undergo surgery (for autologous
blood transfusions) via data extrapolation—without a full
dossier of clinical data for the indication. (For a more de-
tailed review of biosimilar epoetin alfa, see [64].)
Two additional biosimilar versions of Eprex
R , Retacrit
R 
andSilapo
R ,aremanufacturedbyNorbitecGmbH[54,55].
Althoughthisbiosimilarmanufacturer alsousedEprex
R  as
a reference product, the international nonproprietary name
(INN) for these products is epoetin zeta rather than epoetin
alfa. The active substance of epoetin zeta was shown to be a
representative of the active substance found in Eprex
R , and
the protein structures were comparable. However, differ-
ences were noted for the glycosylation profile with respect
to glycoforms without an O-glycan chain and variants of
sialic acid, and a different immunogenicity profile was ob-
servedindogs[65,66].Thecomparabilityofepoetinzetato
Eprex
R  was demonstrated in two randomized clinical tri-
als,acorrectionphasestudyandamaintenancephasestudy,
involving 922 haemodialysis patients with renal anaemia.
Thecorrectionphasestudydemonstratedcomparabilitybe-
tween epoetin zeta and Eprex
R  for mean haemoglobin lev-
els over the evaluation period. However, comparability was
not demonstrated for mean dosage during the evaluation
period. Similar results were reported in the maintenance
phase study, suggesting a possible difference in the bioac-
tivity of epoetin zeta and Eprex
R  [65,66]. Data were also
presented from a study involving 261 cancer patients re-
ceiving chemotherapy, but this study was not designed to
demonstrate therapeutic equivalence between products in
this patient population. Like biosimilar epoetin alfa, epo-
etin zeta was approved for indications in renal anaemia,
chemotherapy-induced anaemia, and for pre-donation of
blood prior to surgery for autologous transfusion [25,26].
Because of its unique INN, epoetin zeta is more readily
distinguished from other epoetin products. Unique INNs
for biopharmaceuticals may help to facilitate accurate
prescribing and dispensing of biopharmaceuticals, as well
as pharmacovigilance [67].
TheCHMPalsoissuedpositiveopinionsforfourbiosim-
ilar filgrastim products for the treatment of neutropeniai34 H. Schellekens
in February of 2008: Ratiograstim
R  and Filgrastim
ratiopharm
R  (Ratiopharm GmbH), Biograstim
R  (CT
Arzneimittel GmbH) and Tevagrastim
R  (Teva Generics
GmbH) [68]. These biosimilar versions of filgrastim were
shown to be similar to the reference product Neupogen
R .
Theseproductsareawaitingfinalmarketingapprovalbythe
EMEA and so the non-clinical and clinical data presented
intheEPARshavenotyetbeenmadeavailabletothepublic.
ItisimportanttorecognizethattheEMEAprovidesarig-
orousandbalancedapproachtotheapprovalprocess.Regu-
lators are attempting to meet the demands of the healthcare
market while ensuring the quality and safety of biopharma-
ceutical products. The approval of these biosimilar prod-
ucts does not substantiate interchangeability with reference
products [69]. Furthermore, the EMEA has not approved
all biosimilar applications. Alpheon
R , a biosimilar version
of Roferon-A
R  (interferon alfa-2a), was recently rejected
by the EMEA. The manufacturer of Alpheon
R  had submit-
ted non-clinical data (protein structure, composition and
purity) on the biosimilar and conducted a randomized con-
trolled trial in 455 patients with hepatitis C to demonstrate
comparable efficacy and safety between the biosimilar and
reference product. The reasons for the rejection by the
EMEA included quality and clinical differences between
Alpheon
R  and the reference product, inadequate data on
the stability of the active substance, inadequate validation
of the process for the finished process and insufficient val-
idation of immunogenicity testing [70].
Conclusions
Biosimilarproductsareverycomplexmoleculesand,there-
fore, cannot be treated the same as conventional generic
drugs. There is a need to comprehensively test biosimilars
during the production process and always in comparison
with an appropriate reference product. Although a variety
of assays are available, they may not be adequate to reli-
ably predict the safety and efficacy of a biosimilar product.
The validation and standardization of assays will be cru-
cial for future testing and regulation of biosimilars. The
regulatory approval of biosimilars will require much more
than the demonstration of pharmaceutical equivalence and
pharmacokinetic bioequivalence associated with conven-
tional generics. In the post-PRCA era, the immunogenicity
of recombinant therapeutic proteins has become a signif-
icant safety concern. Ultimately, only clinical studies and
post-authorization pharmacovigilance to monitor potential
immunogenicity will provide definitive evidence for prod-
uct comparability to the innovator product with respect to
safety and efficacy [14,16].
As manufacturing and clinical experience with the first
biosimilar products accumulates, existing EMEA guide-
lines for the market approval of biosimilars will be re-
vised to include the latest developments and new guide-
lineswillbedeveloped forotherbiosimilarproduct classes.
Outstanding issues will need to be resolved, including
substitution, naming and labelling [67]. Unique naming for
all biopharmaceuticals would likely help to differentiate
these products, which would facilitate accurate prescrib-
ing, dispensing and pharmacovigilance. The labels of the
approvedbiosimilarsarenearlyidenticalorareverysimilar
to those of the reference product. A more transparent label
that included relevant clinical data for the biosimilar, i.e.
the data included in the EPAR, would help clinicians make
informed treatment decisions.
Physician awareness of potential differences between
biopharmaceuticals and biosimilars and the impact on
safety and efficacy is critical for patient safety. Entry of
biosimilars onto the market will require transparent, unbi-
ased dissemination of information to prescribers and other
healthcare professionals. Clinicians need comprehensive
informationonbiosimilars,andbiopharmaceuticalsingen-
eral, to make informed treatment decisions.
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